- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Basilea Pharmaceutica Ltd.
Industry Sector: HealthTechnology
CEO: David Veitch
Number Of Employees: 164
Enterprise Value: $620,586,108
PE Ratio: 6.88
Exchange/Ticker 1: SIX:BSLN
Exchange/Ticker 2: N/A
Latest Market Cap: $646,402,052
BioCentury | Jun 29, 2024
Data Byte
Regeneron’s CD20xCD3 therapy among new recommendations by EMA’s CHMP
Plus: Regulatory body has positive opinion on Winrevair, negative opinions on Syfovre and Translarna
BioCentury | Jan 23, 2024
Deals
Deals roundup: Coherus sharpens oncology focus, BridgeBio bolsters balance sheet and more
BioCentury’s weekly roundup of biopharma deals, Jan. 16-22
BioCentury | Nov 14, 2023
Finance
Nov. 13 Quick Takes: Legend finds next CAR partner in Novartis
Plus: EQT, Forbion lead €129M A round for VectorY and updates from ViaNautis Bio, Cartesian, Aclaris, Anthos, Basilea, and Blueberry
BioCentury | Oct 13, 2022
Management Tracks
Maag becomes CEO at Kyverna
Plus Bernstein to head R&D at Maze, and updates from Visiox, Araris, Quest and Biohaven
BioCentury | May 30, 2020
Management Tracks
Schneyer named Acadia CBO; plus Hansa, MaaT, iOnctura, First Light, Oligomerix, Galecto and Hyloris
BioCentury | Jan 24, 2020
Preclinical News
Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea
BioCentury | May 2, 2019
Company News
Forge, Basilea to develop antibiotics against unexploited targets
BioCentury | Jan 18, 2019
Clinical News
Derazantinib leads to 21% ORR in Phase II intrahepatic cholangiocarcinoma cohort
Items per page:
1 - 10 of 34